Example report. The whole genome example: a public genome from the 1000 Genomes Project, with CYP2D6 Structural Analysis, so you can see what yours will look like. Get your own report

Movement disorders · Involuntary Movement ReducersExample report

Valbenazine

Ingrezza

Use as directed

Your body processes valbenazine faster than most people, but there is no specific FDA guidance for your genotype. The standard dose is typically used.

The genes behind this label

The guidelines read one gene for valbenazine. Each card shows the two copies this person inherited and what they mean.

CYP2D6*2/*2x2

Ultrarapid metabolizer

One copy works normally and one works faster than usual.

3.0 activity scoreTypical: 1.25 to 2.25

Turns on or clears about 1 in 4 prescription drugs. These include many drugs for depression, pain and ADHD.

This result doesn't change the label.

What the guidelines say

What each guideline says about your result.

CYP2D6Ultrarapid metabolizer

FDA drug label

See the FDA table (U.S. Food and Drug Administration, opens in a new tab)

In plain words: Your body processes valbenazine faster than most people, but there is no specific FDA guidance for your genotype. The standard dose is typically used.
What it means: No FDA guidance for your genotype
What the label suggests: Initiate therapy with recommended starting dose.

About valbenazine

Valbenazine (Ingrezza, Ingrezza Sprinkle) treats tardive dyskinesia and the chorea of Huntington's disease in adults.

Used for: Tardive dyskinesia; chorea associated with Huntington's disease (adults)

Others in movement disorders

Compare all 3 movement disorders

Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.

Back to the example report